Hua Medicine

company

About

Hua Medicine is a clinical-stage, innovative drug development company in China.

  • 101 - 250

Details

Last Funding Type
Series B
Last Funding Money Raised
$25M
Industries
Biotechnology,Health Care,Life Science,Medical,Pharmaceutical
Founded date
Jan 1, 2010
Number Of Employee
101 - 250
Operating Status
Active

Hua Medicine is a clinical-stage, innovative drug development company in China, focused on novel therapies for the treatment of diabetes and CNS disorders. Founded by pharma industry veterans and funded by a premier group of international VC investment firms such as Fidelity Asia, Fidelity Biosciences, ARCH Ventures, Venrock, SAIL and WuXi Ventures, the company has in-licensed from major pharma, world-wide rights to a potential best-in-class, oral drug for the treatment of Type 2 Diabetes which utilizes a novel mechanism of action.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
4
$242.40M
Hua Medicine has raised a total of $242.40M in funding over 2 rounds. Their latest funding was raised on Mar 27, 2018 from a Series D round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Mar 27, 2018 Series D $117.40M 1 Detail
Apr 21, 2016 Series C $50M 1 Detail
Jan 8, 2015 Series B $25M 1 Detail
Sep 20, 2011 Series A $50M 2 Detail

Investors

Number of Lead Investors
Number of Investors
2
Hua Medicine is funded by 2 investors. ARCH Venture Partners and Sino-Alliance International Ltd are the most recent investors.
Investor Name Lead Investor Funding Round
ARCH Venture Partners Series D
Sino-Alliance International Ltd Series A